At the Advances in Genome Biology and Technology, AGBT, General Meeting, 10x Genomics (TXG) announced a series of new product innovations to ...

New single cell and spatial innovations extend 10x Genomics' technology and performanceleadership across all three platforms PLEASANT ...

Biotechnology company 10x Genomics and Harvard University reached a Feb. 6 settlement in a patent lawsuit that they jointly ...

Genomics, Inc. (NASDAQ:TXG – Get Free Report) has received a consensus recommendation of “Hold” from the seventeen analysts ...

A Wednesday night earnings report left big questions about how the spending reductions would affect the company.

Leerink Partnrs downgraded shares of 10x Genomics (NASDAQ:TXG – Free Report) from a strong-buy rating to a hold rating in a ...

Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results , but sales fell by 10.3% year on year to $165 million.

Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management ...

Stifel lowered the firm’s price target on 10x Genomics (TXG) to $18 from $21 and keeps a Buy rating on the shares. The funding environment ...

Biotech company 10x Genomics (NASDAQ:TXG) will be reporting earnings tomorrow after market hours. Here’s what to look for. 10x Genomics missed analysts’ revenue expectations by 5% last quarter ...